Jump to ContentJump to Main Navigation
Show Summary Details
More options …

European Pharmaceutical Journal

Acta Facultatis Pharmaceuticae Universitatis Comenianae (formerly)

2 Issues per year


CiteScore 2016: 0.28

SCImago Journal Rank (SJR) 2015: 0.195
Source Normalized Impact per Paper (SNIP) 2015: 0.202

Open Access
Online
ISSN
2453-6725
See all formats and pricing
More options …

Characteristics and Treatment of Hairy Cell Leukaemia

R. Greksák
  • Corresponding author
  • Natonal Cancer Insttute, Department of Clinical Oncology, Bratislava, Slovakia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-08-30 | DOI: https://doi.org/10.2478/afpuc-2014-0002

Abstract

Hairy cell leukaemia (HCL) is a rare chronic indolent lymphoproliferative disease of B-lymphocytes. It always infiltrates the spleen, bone marrow or other organs and is also present in the peripheral blood in more than 95% of cases. The disease takes its name from its characteristic wrinkled surface with hair-like projections. The prognosis of this infaust diagnosis has dramatically changed since the 1980s through more precise diagnosis and efective treatment with purine analogues (1984, 2-deoxycoformy-cine (2-dCF); 1990, 2-chlorodeoxyadenosine (2-CdA)). In our group of 38 patients, we confrmed the diagnostic possibilities and their accuracy; in addition to morphological examination, these include fow cytometric detection of typical surface CD antigens and immunohistochemical recognition of hairy cells in the trephine biopsy. The treatment percentage in the number of response rates (RRs) (100%), complete remissions (CRs) (79%) and overall survival of patients is comparable with previously known data. Overall survival rate without symptoms of disease for more than 10 years after treatment is 87% (33/38). The presence and quantity of minimal residual disease (MRD) after frst-line treatment in bone marrow determine subsequent progression or relapse of the disease, sometimes even occurring many years after the treatment. Probably some new pharmacotherapeutical possibilities (monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors or inhibitors of B-Raf enzyme) could demonstrate the ability to eliminate MRD and cure it in relapsed patients or patients refractory to purine analogues. HCL has become an oncological disease with a relatively good prognosis and long-term survival after standard treatment with purine analogues despite the persistence of indolent MRD in the bone marrow at varying degree of residual infiltration intensity.

Keywords: hairy cell leukaemia; purine analogues; interferon-α; monoclonal antibodies; survival

References

  • [1] Oleske, D. et al. A case-control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol 1985; 121(5): 675-683.PubMedCrossrefGoogle Scholar

  • [2] Arons, E. et al. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009; 114(21): 4687-4695.CrossrefPubMedGoogle Scholar

  • [3] Matutes, E. et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leukemia Lymph, 1994; 14(1): 57-61.Google Scholar

  • [4] Falini, B. et al.: Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004; 363(9424): 869-1871.Google Scholar

  • [5] Tiacci, E. et al.: BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364(24): 2305-2315.Google Scholar

  • [6] Steis, R.G. et al. Serum solubile IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 1988; 71(5): 1304-1309.Google Scholar

  • [7] Polliack, A. Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol 2002; 6(4): 366-388.PubMedGoogle Scholar

  • [8] Hisada, M., et al. Second cancer incidence and cause-specifc mortality among 3104 patients with hairy cell leukaemia: a population-based study. J Natl Cancer Inst 2007; 99(3): 215-222.Web of ScienceCrossrefGoogle Scholar

  • [9] Seshadri, P. and Seshadri, R. Hairy cell leukemia: treatment prospects. Expert Rev Anticancer Ther 2001; 1(1): 91-98.CrossrefGoogle Scholar

  • [10] Golde, D.W. Therapy of hairy-cell leukemia. N Engl J Med 1982; 307(8): 495-496.Google Scholar

  • [11] Frassoldati, A. et al.: Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (IC-GHCL). Leukemia Lymph, 1994; 13(3-4): 307-316.Google Scholar

  • [12] Robak, T. et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999; 62(1): 49-56.PubMedGoogle Scholar

  • [13] Greksák, R. et al. Treatment and prognosis of the patients with hairy cell leukemia, treated in the years 1996 – 2010 at the National Cancer Institute in Bratislava Onkológia 2011; 6(4): 241-245 in slovak.Google Scholar

  • [14] Grever, M.R.: How I treat hairy cell leukemia. Blood 2010; 115(1): 21-28.CrossrefPubMedGoogle Scholar

  • [15] Greksák, R.: Establishment of the diagnosis and minimal residual disease in hairy cell leukaemia by fow cytom-etry of bone marrow aspirate and imunohistochemical examination of trepanobiopsy. In Onkológia, 2012; 7(6): 406-409 in slovak.Google Scholar

  • [16] Greksák, R. Hairy cell leukaemia – diagnostics, treatment and monoclonal antibodies, In Transfuze Hematol dnes, 2010; 16(3): 158-165 in slovak.Google Scholar

About the article

Received: 2014-02-14

Accepted: 2014-04-02

Published Online: 2014-08-30


Citation Information: Acta Facultatis Pharmaceuticae Universitatis Comenianae, ISSN (Online) 1338-6786, DOI: https://doi.org/10.2478/afpuc-2014-0002.

Export Citation

© Acta Facultatis Pharmaceuticae Universitatis Comenianae. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in